Differentiation of Li-Fraumeni Syndrome (LFS) Patient-derived Induced Pluripotent Stem Cell (iPSC) to Mesenchymal Stem Cell (MSC) (Days 0 - 28)
2:19
iPSC-derived MSC Maturation (Day 28 - 45) and Differentiation of LFS MSC to Osteoblasts (Day 0 - 24)
4:33
Xenograft In Vivo Tumorigenesis Model Setup
6:39
Results: Representative LFS MSC Differentiation
8:10
Conclusion
Transcript
This Li-Fraumeni syndrome iPSC-based osteosarcoma model can help answer key questions in the osteosarcoma research field about using patient iP cells in cancer modeling. The main advantage of this model is that it allows the generation unlimited c
Sign in or start your free trial to access this content
Ici, nous présentons un protocole pour la génération de pluripotentes induites des cellules souches (CISP) de Syndrome de Li-Fraumeni (LFS) patient dérivée fibroblastes, différenciation de CISP par l’intermédiaire de cellules souches mésenchymateuses (CSM) d’ostéoblastes et modélisation in vivo tumorigenèse utilisant des ostéoblastes patient dérivé de LFS.